Target intelligence / Profile preview

Sulfonylurea receptor 2A (SUR2A)

Target
SUR2A
Molecular classification
Transporter (ABC transporter family), Regulatory subunit of ion channel (KATP channel), Membrane protein
01

Overview

Sulfonylurea receptor 2A (SUR2A) is a large transmembrane protein that forms part of the ATP-sensitive potassium channel complex in the heart and other tissues. It acts as the regulatory subunit, binding and hydrolyzing ATP to control the opening and closing of the channel in response to cellular metabolic status. SUR2A is encoded by the ABCC9 gene and is a member of the ABC transporter family. It is the molecular target of drugs such as sulfonylureas, which regulate channel activity and downstream cell excitability. Mutations in SUR2A are implicated in certain cardiovascular diseases and may contribute to altered drug responses. Drugs targeting SUR2A modulate its ability to control the flow of potassium ions, which directly affects cell membrane polarization and protection from metabolic stress.

Other names
SUR2AATP-binding cassette sub-family C member 9 (cardiac isoform)ABCC9 (gene symbol)
02

Mechanism of action

Drugs bind the SUR2A subunit to modulate KATP channel activity: Sulfonylureas inhibit channel, depolarizing cell membrane; Potassium channel openers activate channel, hyperpolarizing membrane

03

Biological functions

Regulation of KATP channel gating via nucleotide binding/hydrolysisCellular energy sensingModulation of membrane excitabilityProtection against metabolic stress (e.g., ischemia in cardiac tissue)
04

Disease associations

Cardiovascular disease (mutations can cause heart disorders)Diabetes (target of anti-diabetic drugs in pancreatic β cells, though SUR2A is more cardiac/vascular)Other disorders related to ion channel dysfunction
05

Safety considerations

Cardiac arrhythmia (risk if channel modulation is excessive)Off-target effects (e.g., hypoglycemia, though SUR1 is more prominent here)Variable drug response due to genetic polymorphisms
06

Interacting drugs

Sulfonylureas (as a pharmacological class, e.g., glibenclamide, glimepiride; direct action is better characterized for SUR1 but SUR2A also binds sulfonylureas)

2 more in the full profile.

07

Biomarkers

Specific ABCC9 gene mutations (potential for diagnostic/prognostic use in channelopathies and some cardiac syndromes)Response to sulfonylureas (primarily characterized for SUR1, less for SUR2A)

Beyond the preview

Go deeper on Sulfonylurea receptor 2A (SUR2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sulfonylurea receptor 2A (SUR2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call